Results 101 to 110 of about 283,745 (306)

Encorafenib with binimetinib efficacy in the first, second, and third line of treatment for patients with advanced melanoma harboring a BRAF mutation — real-world study

Oncology in Clinical Practice
INTRODUCTION: In patients with advanced melanoma with BRAF mutation, the BRAF and MEK inhibitors can be used before or after immunotherapy, and even as third-line systemic treatment.
Anna M. Czarnecka, Piotr Błoński, Bożena Cybulska-Stopa, Wiesław Bal, Robert Dziura, Magdalena Ciążyńska, Krzysztof Ostraszewski, Katarzyna Krawczak, Łukasz Galus, Katarzyna Kozak, Natasza Kempa-Kamińska, Grażyna Kamińska-Winciorek, Marta Pabianek, Paweł Rogala, Tomasz Kubiatowski, Marcin Ziętek, Jacek Mackiewicz, Piotr Rutkowski   +17 more
doaj   +1 more source

The Chick Embryo as an Experimental System for Melanoma Cell Invasion

PLoS ONE, 2013
A primary cutaneous melanoma will not kill the patient, but its metastases. Since in vitro studies on melanoma cells in 2-D cultures do often not reflect reality, 3-D models might come closer to the physiological situation in the patient during cancer initiation and progression.Here, we describe the chick embryo model for in vivo studies of melanoma ...
Christian Busch, Jelena Krochmann, Ulrich Drews   +2 more
openaire   +3 more sources

Matrix Viscoelasticity Regulates Dendritic Cell Migration and Immune Priming

Advanced Materials, EarlyView.
Matrix viscoelasticity is a key mechanical feature of the tumor microenvironment but remains poorly understood in immune regulation. Here, we develop a tunable collagen platform to decouple viscoelasticity from stiffness and show that slow‐relaxing matrices constrain dendritic cell migration by limiting actomyosin‐driven matrix remodeling, thereby ...
Wei‐Hung Jung, Emie Humann, Joshua M. Price, Yoav Binenbaum, Azra Haseki, Sanjana Iyer, David J. Mooney   +6 more
wiley   +1 more source

Pre‐Encoded IFN‐I Sensitivity Exacerbates Memory T Cell Senescence in Solid Tumors

Advanced Science, EarlyView.
Type I interferon (IFN‐I) signaling promotes p21‐dependent cell cycle arrest in senescent tumor‐specific memory T cells, resulting in poor proliferative responses and solid tumor regression during cancer vaccination. Conversely, IFNα/β receptor blockade reinvigorates T cell proliferation to regress solid tumors and is more effective with increasing ...
Andrew Nguyen, Scott R Walsh, Li Deng, Lan Chen, Yonghong Wan   +4 more
wiley   +1 more source

Bevacizumab Suppression of Establishment of Micrometastases in Experimental Ocular Melanoma

Investigative Opthalmology & Visual Science, 2010
This study was undertaken to determine whether anti-vascular endothelial growth factor (VEGF) therapy inhibits growth of primary uveal melanoma and spread of its hepatic micrometastases.The human uveal melanoma cell lines Mel290 and Mel 270, HUVECs, mouse B16LS9 melanoma cells, and mouse vascular endothelial cells were separately cultured or co ...
Yang, H., Jager, M.J., Grossniklaus, H.E.   +2 more
openaire   +4 more sources

PD‐1 Inhibits CD4+ TRM‐Mediated cDC1 Mobilization via Suppressing JAML in Human NSCLC

Advanced Science, EarlyView.
CD4+ tissue‐resident memory T cells (TRMs) in non‐small cell lung cancer recruit conventional type 1 dendritic cells via XCL1‐XCR1 signaling, orchestrating antitumor immunity. The costimulatory molecule JAML is essential for this process. PD‐1 blockade restores JAML expression and cDC1 mobilization, while JAML agonists synergize with anti‐PD‐1 therapy,
Zheyu Shao, Qinyuan Liu, Zhongwei Xin, Zhiyao Zhou, Mingjie Lin, Di Chen, Zhixing Hao, Yongyuan Chen, Wenxuan Wu, Shuyang Zhang, Xiaoke Chen, Xia Xu, Jinfan Li, Wei Lin, Yuhao Lu, Dang Wu, Pin Wu   +16 more
wiley   +1 more source

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

Advanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun, Haochen Yang, Qing Xu, Xingya Li, Jinxing Lou, Jianchun Duan, Jiachen Xu, Zhuqing Liu, Yong Xia, Zhicai Lin, Linlin Li, Dan Sun, Jiaguo Li, Tao Liu, Jun Guo, Wenfeng Xu, Weimin Zhu, Yi Liu, Boyang Sun, Jia Zhong, Lijie Rong, Qijun Qian, Chenqi Xu, Jie Wang   +23 more
wiley   +1 more source

RNF213 Is an Interferon‐Stimulated Gene That Targets Influenza A Virus NP and Activates MDA5 to Restrict Infection

Advanced Science, EarlyView.
RNF213 is characterized as a dual‐functional antiviral effector. It directly mediates the degradation of the influenza A virus nucleoprotein (NP) while simultaneously activating the MDA5‐mediated innate immune signaling pathway. This coordinated response establishes a powerful host defense system against viral infection. ABSTRACT Influenza A virus (IAV)
Haoning Li, Yuying Zhang, Jingjing Wang, Qianqian Zhang, Hailiang Sun, Fanhua Wei   +5 more
wiley   +1 more source

Approaches to decision-making among late-stage melanoma patients: a multifactorial investigation. [PDF]

, 2019
PurposeThe treatment decisions of melanoma patients are poorly understood. Most research on cancer patient decision-making focuses on limited components of specific treatment decisions.
Abramson, Corey M, Dohan, Daniel, Garrett, Sarah B, Rendle, Katharine A   +3 more
core  

Promising Experimental Therapies for Metastatic Melanoma

, 2011
Advanced melanoma has the highest per-death loss of years of potential life expectancy second only to adult leukemia. The incidence of melanoma continues to rise worldwide at approximately 3% per year, and in 2009 there were an estimated 68,720 new cases in the United States and 8650 deaths (Balch et al. 2009).
Bao Lam, Patrick A., Anna C.
openaire   +2 more sources